TY - JOUR T1 - Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 307 LP - 317 DO - 10.3949/ccjm.90a.22032 VL - 90 IS - 5 AU - Randol Kennedy AU - Hussein Awada AU - Naga Vura AU - Daniela Ciltea AU - Michael Morocco Y1 - 2023/05/01 UR - http://www.ccjm.org/content/90/5/307.abstract N2 - Immune checkpoint inhibitors are used more and more to treat several types of cancer, significantly extending cancer-free survival. However, concerns are growing about their toxic effects, which are many and varied. Endocrinopathies are some of the most frequently reported adverse effects, and thyroid dysfunction is the most common of these. Here, we review the incidence and severity of each immune checkpoint inhibitor-related endocrinopathy, possible factors related to toxicity risk, and principles of management. ER -